What is the projected market valuation of the Cancer Diagnostics Market by 2035?

The Cancer Diagnostics Market is projected to reach a valuation of 386.19 USD Billion by 2035. Read More

What was the market valuation of the Cancer Diagnostics Market in 2024?

In 2024, the Cancer Diagnostics Market was valued at 189.19 USD Billion. Read More

What is the expected CAGR for the Cancer Diagnostics Market from 2025 to 2035?

The expected CAGR for the Cancer Diagnostics Market during the forecast period 2025 - 2035 is 6.7%. Read More

Which test type segment is projected to have the highest valuation by 2035?

The Molecular Testing segment is projected to reach a valuation of 146.19 USD Billion by 2035. Read More

What are the projected valuations for blood tests in the Cancer Diagnostics Market by 2035?

Blood Tests are expected to reach a valuation of 80.0 USD Billion by 2035. Read More

Which cancer type segment is anticipated to grow the most by 2035?

Breast Cancer is anticipated to grow significantly, reaching a valuation of 90.0 USD Billion by 2035. Read More

What is the expected market size for diagnostic laboratories by 2035?

Diagnostic Laboratories are projected to reach a market size of 120.0 USD Billion by 2035. Read More

What sample type is expected to have the highest valuation in the Cancer Diagnostics Market by 2035?

Blood Samples are expected to have the highest valuation, reaching 140.0 USD Billion by 2035. Read More

Who are the key players in the Cancer Diagnostics Market?

Key players in the Cancer Diagnostics Market include Roche, Abbott, Thermo Fisher Scientific, and Siemens Healthineers. Read More

What is the projected valuation for lung cancer diagnostics by 2035?

Lung Cancer diagnostics are projected to reach a valuation of 80.0 USD Billion by 2035. Read More

Cancer Diagnostics Market

Cancer Diagnostics Market Research Report: Size, Share, Trend Analysis By Test Type (Biopsy, Imaging, Blood Tests, Molecular Testing), By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer), By End Users (Hospitals, Diagnostic Laboratories, Research Institutes), By Sample Type (Tissue Samples, Blood Samples, Urine Samples) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

6.7%

2024 Market Size

$ 189.19 Billion

2035 Market Size

$ 386.19 Billion

Medical Device ● Updated June 2026 Report ID: MRFR/MED/1430-HCR | Pages: 200 | Author: Satyendra Maurya, Rahul Gotadki

Summary Table of Contents Segmentation Methodology Download PDF

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Healthcare, BY Test Type (USD Billion) | |
  1. 4.1.1 Biopsy | |
  2. 4.1.2 Imaging | |
  3. 4.1.3 Blood Tests | |
  4. 4.1.4 Molecular Testing |
2. 4.2 Healthcare, BY Cancer Type (USD Billion) | |
  1. 4.2.1 Breast Cancer | |
  2. 4.2.2 Lung Cancer | |
  3. 4.2.3 Prostate Cancer | |
  4. 4.2.4 Colorectal Cancer |
3. 4.3 Healthcare, BY End User (USD Billion) | |
  1. 4.3.1 Hospitals | |
  2. 4.3.2 Diagnostic Laboratories | |
  3. 4.3.3 Research Institutes |
4. 4.4 Healthcare, BY Sample Type (USD Billion) | |
  1. 4.4.1 Tissue Samples | |
  2. 4.4.2 Blood Samples | |
  3. 4.4.3 Urine Samples |
5. 4.5 Healthcare, BY Region (USD Billion) | |
  1. 4.5.1 North America | | |
    1. 4.5.1.1 US | | |
    2. 4.5.1.2 Canada | |
  2. 4.5.2 Europe | | |
    1. 4.5.2.1 Germany | | |
    2. 4.5.2.2 UK | | |
    3. 4.5.2.3 France | | |
    4. 4.5.2.4 Russia | | |
    5. 4.5.2.5 Italy | | |
    6. 4.5.2.6 Spain | | |
    7. 4.5.2.7 Rest of Europe | |
  3. 4.5.3 APAC | | |
    1. 4.5.3.1 China | | |
    2. 4.5.3.2 India | | |
    3. 4.5.3.3 Japan | | |
    4. 4.5.3.4 South Korea | | |
    5. 4.5.3.5 Malaysia | | |
    6. 4.5.3.6 Thailand | | |
    7. 4.5.3.7 Indonesia | | |
    8. 4.5.3.8 Rest of APAC | |
  4. 4.5.4 South America | | |
    1. 4.5.4.1 Brazil | | |
    2. 4.5.4.2 Mexico | | |
    3. 4.5.4.3 Argentina | | |
    4. 4.5.4.4 Rest of South America | |
  5. 4.5.5 MEA | | |
    1. 4.5.5.1 GCC Countries | | |
    2. 4.5.5.2 South Africa | | |
    3. 4.5.5.3 Rest of MEA 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Healthcare | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 Roche (CH) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Abbott (US) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Thermo Fisher Scientific (US) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 Siemens Healthineers (DE) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 Illumina (US) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Bristol-Myers Squibb (US) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Agilent Technologies (US) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 Qiagen (NL) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 Hologic (US) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 NORTH AMERICA MARKET ANALYSIS |
6. 6.3 US MARKET ANALYSIS BY TEST TYPE |
7. 6.4 US MARKET ANALYSIS BY CANCER TYPE |
8. 6.5 US MARKET ANALYSIS BY END USER |
9. 6.6 US MARKET ANALYSIS BY SAMPLE TYPE |
10. 6.7 CANADA MARKET ANALYSIS BY TEST TYPE |
11. 6.8 CANADA MARKET ANALYSIS BY CANCER TYPE |
12. 6.9 CANADA MARKET ANALYSIS BY END USER |
13. 6.10 CANADA MARKET ANALYSIS BY SAMPLE TYPE |
14. 6.11 EUROPE MARKET ANALYSIS |
15. 6.12 GERMANY MARKET ANALYSIS BY TEST TYPE |
16. 6.13 GERMANY MARKET ANALYSIS BY CANCER TYPE |
17. 6.14 GERMANY MARKET ANALYSIS BY END USER |
18. 6.15 GERMANY MARKET ANALYSIS BY SAMPLE TYPE |
19. 6.16 UK MARKET ANALYSIS BY TEST TYPE |
20. 6.17 UK MARKET ANALYSIS BY CANCER TYPE |
21. 6.18 UK MARKET ANALYSIS BY END USER |
22. 6.19 UK MARKET ANALYSIS BY SAMPLE TYPE |
23. 6.20 FRANCE MARKET ANALYSIS BY TEST TYPE |
24. 6.21 FRANCE MARKET ANALYSIS BY CANCER TYPE |
25. 6.22 FRANCE MARKET ANALYSIS BY END USER |
26. 6.23 FRANCE MARKET ANALYSIS BY SAMPLE TYPE |
27. 6.24 RUSSIA MARKET ANALYSIS BY TEST TYPE |
28. 6.25 RUSSIA MARKET ANALYSIS BY CANCER TYPE |
29. 6.26 RUSSIA MARKET ANALYSIS BY END USER |
30. 6.27 RUSSIA MARKET ANALYSIS BY SAMPLE TYPE |
31. 6.28 ITALY MARKET ANALYSIS BY TEST TYPE |
32. 6.29 ITALY MARKET ANALYSIS BY CANCER TYPE |
33. 6.30 ITALY MARKET ANALYSIS BY END USER |
34. 6.31 ITALY MARKET ANALYSIS BY SAMPLE TYPE |
35. 6.32 SPAIN MARKET ANALYSIS BY TEST TYPE |
36. 6.33 SPAIN MARKET ANALYSIS BY CANCER TYPE |
37. 6.34 SPAIN MARKET ANALYSIS BY END USER |
38. 6.35 SPAIN MARKET ANALYSIS BY SAMPLE TYPE |
39. 6.36 REST OF EUROPE MARKET ANALYSIS BY TEST TYPE |
40. 6.37 REST OF EUROPE MARKET ANALYSIS BY CANCER TYPE |
41. 6.38 REST OF EUROPE MARKET ANALYSIS BY END USER |
42. 6.39 REST OF EUROPE MARKET ANALYSIS BY SAMPLE TYPE |
43. 6.40 APAC MARKET ANALYSIS |
44. 6.41 CHINA MARKET ANALYSIS BY TEST TYPE |
45. 6.42 CHINA MARKET ANALYSIS BY CANCER TYPE |
46. 6.43 CHINA MARKET ANALYSIS BY END USER |
47. 6.44 CHINA MARKET ANALYSIS BY SAMPLE TYPE |
48. 6.45 INDIA MARKET ANALYSIS BY TEST TYPE |
49. 6.46 INDIA MARKET ANALYSIS BY CANCER TYPE |
50. 6.47 INDIA MARKET ANALYSIS BY END USER |
51. 6.48 INDIA MARKET ANALYSIS BY SAMPLE TYPE |
52. 6.49 JAPAN MARKET ANALYSIS BY TEST TYPE |
53. 6.50 JAPAN MARKET ANALYSIS BY CANCER TYPE |
54. 6.51 JAPAN MARKET ANALYSIS BY END USER |
55. 6.52 JAPAN MARKET ANALYSIS BY SAMPLE TYPE |
56. 6.53 SOUTH KOREA MARKET ANALYSIS BY TEST TYPE |
57. 6.54 SOUTH KOREA MARKET ANALYSIS BY CANCER TYPE |
58. 6.55 SOUTH KOREA MARKET ANALYSIS BY END USER |
59. 6.56 SOUTH KOREA MARKET ANALYSIS BY SAMPLE TYPE |
60. 6.57 MALAYSIA MARKET ANALYSIS BY TEST TYPE |
61. 6.58 MALAYSIA MARKET ANALYSIS BY CANCER TYPE |
62. 6.59 MALAYSIA MARKET ANALYSIS BY END USER |
63. 6.60 MALAYSIA MARKET ANALYSIS BY SAMPLE TYPE |
64. 6.61 THAILAND MARKET ANALYSIS BY TEST TYPE |
65. 6.62 THAILAND MARKET ANALYSIS BY CANCER TYPE |
66. 6.63 THAILAND MARKET ANALYSIS BY END USER |
67. 6.64 THAILAND MARKET ANALYSIS BY SAMPLE TYPE |
68. 6.65 INDONESIA MARKET ANALYSIS BY TEST TYPE |
69. 6.66 INDONESIA MARKET ANALYSIS BY CANCER TYPE |
70. 6.67 INDONESIA MARKET ANALYSIS BY END USER |
71. 6.68 INDONESIA MARKET ANALYSIS BY SAMPLE TYPE |
72. 6.69 REST OF APAC MARKET ANALYSIS BY TEST TYPE |
73. 6.70 REST OF APAC MARKET ANALYSIS BY CANCER TYPE |
74. 6.71 REST OF APAC MARKET ANALYSIS BY END USER |
75. 6.72 REST OF APAC MARKET ANALYSIS BY SAMPLE TYPE |
76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
77. 6.74 BRAZIL MARKET ANALYSIS BY TEST TYPE |
78. 6.75 BRAZIL MARKET ANALYSIS BY CANCER TYPE |
79. 6.76 BRAZIL MARKET ANALYSIS BY END USER |
80. 6.77 BRAZIL MARKET ANALYSIS BY SAMPLE TYPE |
81. 6.78 MEXICO MARKET ANALYSIS BY TEST TYPE |
82. 6.79 MEXICO MARKET ANALYSIS BY CANCER TYPE |
83. 6.80 MEXICO MARKET ANALYSIS BY END USER |
84. 6.81 MEXICO MARKET ANALYSIS BY SAMPLE TYPE |
85. 6.82 ARGENTINA MARKET ANALYSIS BY TEST TYPE |
86. 6.83 ARGENTINA MARKET ANALYSIS BY CANCER TYPE |
87. 6.84 ARGENTINA MARKET ANALYSIS BY END USER |
88. 6.85 ARGENTINA MARKET ANALYSIS BY SAMPLE TYPE |
89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TEST TYPE |
90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY CANCER TYPE |
91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER |
92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY SAMPLE TYPE |
93. 6.90 MEA MARKET ANALYSIS |
94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY TEST TYPE |
95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY CANCER TYPE |
96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY END USER |
97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY SAMPLE TYPE |
98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY TEST TYPE |
99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY CANCER TYPE |
100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY END USER |
101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY SAMPLE TYPE |
102. 6.99 REST OF MEA MARKET ANALYSIS BY TEST TYPE |
103. 6.100 REST OF MEA MARKET ANALYSIS BY CANCER TYPE |
104. 6.101 REST OF MEA MARKET ANALYSIS BY END USER |
105. 6.102 REST OF MEA MARKET ANALYSIS BY SAMPLE TYPE |
106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
107. 6.104 RESEARCH PROCESS OF MRFR |
108. 6.105 DRO ANALYSIS OF HEALTHCARE |
109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
112. 6.109 HEALTHCARE, BY TEST TYPE, 2024 (% SHARE) |
113. 6.110 HEALTHCARE, BY TEST TYPE, 2024 TO 2035 (USD Billion) |
114. 6.111 HEALTHCARE, BY CANCER TYPE, 2024 (% SHARE) |
115. 6.112 HEALTHCARE, BY CANCER TYPE, 2024 TO 2035 (USD Billion) |
116. 6.113 HEALTHCARE, BY END USER, 2024 (% SHARE) |
117. 6.114 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion) |
118. 6.115 HEALTHCARE, BY SAMPLE TYPE, 2024 (% SHARE) |
119. 6.116 HEALTHCARE, BY SAMPLE TYPE, 2024 TO 2035 (USD Billion) |
120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
121. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.2.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  3. 7.2.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.2.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.3.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.3.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  3. 7.3.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.3.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.4.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.4.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  3. 7.4.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.4.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.5.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.5.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  3. 7.5.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.5.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.6.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.6.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  3. 7.6.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.6.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.7.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.7.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  3. 7.7.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.7.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.8.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.8.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  3. 7.8.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.8.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.9.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.9.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  3. 7.9.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.9.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.10.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.10.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  3. 7.10.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.10.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.11.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.11.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  3. 7.11.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.11.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.12.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.12.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  3. 7.12.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.12.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.13.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.13.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  3. 7.13.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.13.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.14.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.14.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  3. 7.14.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.14.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.15.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.15.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  3. 7.15.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.15.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.16.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.16.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  3. 7.16.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.16.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.17.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.17.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  3. 7.17.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.17.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.18.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.18.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  3. 7.18.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.18.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.19.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.19.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  3. 7.19.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.19.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.20.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.20.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  3. 7.20.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.20.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.21.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.21.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  3. 7.21.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.21.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.22.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.22.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  3. 7.22.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.22.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.23.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.23.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  3. 7.23.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.23.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.24.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.24.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  3. 7.24.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.24.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.25.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.25.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  3. 7.25.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.25.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.26.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.26.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  3. 7.26.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.26.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.27.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.27.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  3. 7.27.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.27.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.28.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.28.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  3. 7.28.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.28.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.29.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.29.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  3. 7.29.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.29.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.30.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.30.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  3. 7.30.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.30.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.31.1 |
152. 7.32 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

Cancer Diagnostics Market Segmentation

Cancer Diagnostics Market By Test Type (USD Billion, 2025-2035)

Biopsy
Imaging
Blood Tests
Molecular Testing

Cancer Diagnostics Market By Cancer Type (USD Billion, 2025-2035)

Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer

Cancer Diagnostics Market By End User (USD Billion, 2025-2035)

Hospitals
Diagnostic Laboratories
Research Institutes

Cancer Diagnostics Market By Sample Type (USD Billion, 2025-2035)

Tissue Samples
Blood Samples
Urine Samples

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”